[ad_1]

Company Logo

Dublin, June 16, 2022 (GLOBE NEWSWIRE) — The “Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028” drug pipelines has been added to ResearchAndMarkets.com’s providing.

Global CAR T cell remedy market alternative is anticipated to surpass US$ 15 Billion by 2028

The improvement of CAR T cell remedy will collect momentum from the growing variety of traders, designers, and analysts within the information remedy.

Rising frequencies of most cancers throughout the globe along with the relentless technological development for reliable and efficient most cancers therapy is anticipated to help the expansion of the worldwide CAR-T cell remedy market. Furthermore, heavy investments in scientific analysis and improvement in cell remedy are estimated to spice up the marketplace for CAR-T cell remedy within the years to come back.

The report supplies data on the globally accepted CAR T cell therapies together with their value, dosage, and gross sales evaluation. The report analyzes and forecasts the scale of the worldwide CAR-T cell remedy market.

The report delivers a full-scale exploration of market dynamics and components which might be manipulating the expansion of the worldwide CAR-T cell remedy market. The report additionally offers a aggressive evaluation of main market gamers that can give a aggressive benefit to clients of their respective companies.

Chimeric antigen receptor (CAR) T cell remedy is a novel immunotherapeutic strategy that’s indicated for the administration of most cancers. CAR T-cell remedy is a kind of remedy wherein the T-cells are taken from the blood of the affected person, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor).

This aids in higher recognizing of particular most cancers cell antigens. The CAR T-cells are then given again to the affected person. To date, 6 CAR T-cell remedy merchandise together with Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been accepted by FDA for the administration of big selection of cancers. In addition to this, Relmacabtagene autoleucel have been accepted in China.

The introduction of CAR T cell therapies has proven excessive adoption charges in a brief span of time has propelled additional analysis and improvement actions on this area. Apart from hematological malignancies, the researchers are additionally increasing the function of CAR T cell therapies in strong tumors which is able to propel the expansion of the market.

Story continues

For occasion, a current analysis examine demonstrated that infusing immune cells into sufferers has proven early promise by shrinking tumors in digestive system. The interim outcomes demonstrated that tumors in almost 50% of the 37 sufferers to this point contracted after the remedy.

The world CAR T cell remedy market is extremely consolidated with a number of key gamers. The pharmaceutical giants out there are more and more partnering or collaborating with know-how corporations to combine superior applied sciences for the betterment of CAR-T remedy or to develop their geographical presence.

For occasion, Bayer and Atara Biotherapeutics entered right into a worldwide license settlement for the event of next-generation ATA3271 which is mesothelin-directed CAR-T cell remedy. The settlement additionally goals to develop ATA2271, for the administration of excessive mesothelin-expressing tumors resembling malignant pleural mesothelioma and non-small-cell lung most cancers.

Among drug sorts, Yescarta is at the moment dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the therapy of grownup sufferers with relapsed or refractory massive B-cell lymphoma after two or extra strains of systemic remedy, together with diffuse massive B-cell lymphoma.

Recently in 2022, regulatory our bodies expanded the approval of medication for the administration of enormous B-cell lymphoma (LBCL) that’s refractory to first-line chemoimmunotherapy or relapses inside a yr of first-line chemotherapy. The big selection of therapeutic indications in addition to the worldwide availability of the drug is the key components that are the key components aiding within the dominance of those components.

Report Highlights:

Research Methodology

Global CAR T Cell Therapy Market Opportunity > USD 15 Billion

Global & Regional Market Insight: Current & Market Forecast 2028

Approved CAR T Cell Therapies Sales Forecast Till 2028

Emerging In Vivo Induced CAR T Cell Therapies

CAR T Cell Therapy Manufacturing Cost Analysis

CAR T Cell Therapy Approval & Reimbursement Scenario By Country

Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies

Insight On More Than 600 CAR T Cell Therapies In Clinical Trials

CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase

Key Topics Covered:

1. Research Methodology

2. Chimeric Antigen Receptor (CAR) T Cell Therapy – Next Era in Immuno Oncology

3. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
3.1 Structure of CAR-T Cell
3.2 1st Generation Chimeric Antigen Receptor
3.3 2nd & third Generation CAR-T Cell
3.4 Principle of Chimeric Antigen Receptor Design

4. Approaches to Improve the Efficiency of CAR-T Cell Therapy

5. CAR T Cell Therapy Manufacturing Cost Analysis

6. Emerging In-Vivo Induced CAR T Cell Therapies
6.1 Need of In-Vivo CAR T Cell Therapy
6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR
6.3 Key Drug in Research & Development

7. Global CAR T Cell Therapy Market Outlook 2022 – 2028
7.1 Market Overview
7.2 Future Market Opportunity

8. Globally Approved CAR T Cell Therapies – Pricing, Dosage & Sales Analysis 2028
8.1 Tisagenlecleucel (Kymriah)
8.2 Axicabtagene Ciloleuce (Yescarta)
8.3 Brexucabtagene Autoleucel (Tecartus)
8.4 Lisocabtagene maraleucel (Breyanzi)
8.5 Idecabtagene Vicleucel (Abecma)
8.6 Relmacabtagene autoleucel (Carteyva)
8.7 Ciltacabtagene autoleucel (Carvykti)

9. US CAR T Cell Therapy Market Outlook
9.1 Approved & Key CAR T Cell Therapy Products in US
9.2 Market Overview
9.3 Current Reimbursement Scenario

10. Europe CAR T Cell Therapy Market Outlook
10.1 Approved & Key CAR T Cell Therapy Products in Europe
10.2 UK
10.3 Germany
10.4 Spain
10.5 France
10.6 Rest of Europe
10.7 Current Reimbursement Scenario

11. China CAR T Cell Therapy Market Outlook
11.1 Approved & Key CAR T Cell Therapy Products in China
11.2 Current Market Size & Forecast

12. Japan CAR T Cell Therapy Market Outlook
12.1 Approved & Key CAR T Cell Therapy Products in Japan
12.2 Market Overview
12.3 Current Reimbursement Scenario

13. South Korea CAR T Cell Therapy Market Outlook
13.1 Approved & Key CAR T Cell Therapies in South Korea
13.2 Future Market Opportunity

14. Australia CAR T Cell Therapy Market Outlook
14.1 Approved & Key CAR T Cell Products in Australia
14.2 Australia CAR T Cell Therapy Market
14.3 Current Reimbursement Scenario

15. Taiwan CAR T Cell Therapy Market Outlook

16. Global CAR T Cells Clinical Pipeline Overview
16.1 By Company
16.2 By County
16.3 By Indication
16.4 By Phase

17. Global CAR T Cells Clinical Pipeline By Company, Indication & Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-I
17.5 Phase-I/II
17.6 Phase-II
17.7 Phase-III
17.8 Registered

18. Marketed CAR T Cell Therapy Clinical perception
18.1 Breyanzi
18.2 CARVYKTI
18.3 Yescarta
18.4 Kymriah
18.5 Abecma
18.6 Tecartus

19. Global CAR-T Cell Therapy Market Dynamics
19.1 Favorable Parameters
19.2 Market Challenges

20. Competitive Landscape
20.1 Autolus
20.2 Bellicum
20.3 Bluebird
20.4 Celgene
20.5 Cellectis
20.6 Celyad
20.7 Eureka Therapeutics
20.8 Fortress Biotech
20.9 Immune Therapeutics
20.10 Juno Therapeutics
20.11 Kite Pharma
20.12 Novartis
20.13 Sorrento therapeutics
20.14 TILT Biotherapeutics
20.15 Ziopharm

For extra details about this drug pipelines report go to https://www.researchandmarkets.com/r/4xxf5g

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

[ad_2]

Source link

#Global #CAR #Cell #Therapy #Market #Research #Opportunity #Clinical #Pipeline #Insights

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published.